Literature DB >> 7050326

Effect of intensive insulin treatment on linear growth in the young diabetic patient.

M C Rudolf, R S Sherwin, R Markowitz, S E Bates, M Genel, J Hochstadt, W V Tamborlane.   

Abstract

Although impaired growth is a well-recognized complication of uncontrolled diabetes, it has not been established whether less severe metabolic derangements commonly seen with conventional treatment adversely affected growth potential. To examine this question, growth velocity was measured in nine type 1 diabetic patients (age 14 +/- 3 years) before and after six months of intensive insulin treatment either with the insulin pump or with multiple injections, which lowered mean plasma glucose concentration from 270 +/- 96 to 105 +/- 55 mg/dl and total glycosylated hemoglobin from 12.4 +/- 3.0 to 8.4 +/- 1.5% (mean +/- SD). During conventional treatment, growth velocity (5.3 +/- 2.2 cm/year) was within the range of normal despite elevations in plasma glucose concentrations. However, growth velocity increased sharply during intensive treatment (to 9.4 +/- 3.9 cm/year, P less than 0.005), reaching values in excess of normal in seven patients. The increase in growth velocity observed during intensive treatment was associated with a twofold rise in plasma somatomedin-C values. Skeletal maturation, previously normal or slightly delayed, did not advance excessively. These data indicate that the metabolic changes accompanying intensive treatment may enhance growth in diabetic children, even in those with apparently normal growth velocity during conventional therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7050326     DOI: 10.1016/s0022-3476(82)80054-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  14 in total

1.  Nervous System Expression of PPARγ and Mutant PPARγ Has Profound Effects on Metabolic Regulation and Brain Development.

Authors:  Madeliene Stump; Deng-Fu Guo; Ko-Ting Lu; Masashi Mukohda; Martin D Cassell; Andrew W Norris; Kamal Rahmouni; Curt D Sigmund
Journal:  Endocrinology       Date:  2016-08-30       Impact factor: 4.736

2.  Diabetes. II. Strict glycaemic control.

Authors:  D A Price
Journal:  Arch Dis Child       Date:  1984-09       Impact factor: 3.791

3.  Diabetes. I. Measuring adequacy and lability of control.

Authors:  R B Tattersall
Journal:  Arch Dis Child       Date:  1984-09       Impact factor: 3.791

4.  Insulin exerts metabolic and growth-promoting effects by a direct action on the liver in vivo: clarification of the functional significance of the portal vascular link between the beta cells of the pancreatic islets and the liver.

Authors:  S C Griffen; S M Russell; L S Katz; C S Nicoll
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 5.  Carbohydrate metabolism in uremia.

Authors:  R H Mak
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

6.  Growth and growth factors in diabetes mellitus.

Authors:  S Salardi; S Tonioli; P Tassoni; M Tellarini; L Mazzanti; E Cacciari
Journal:  Arch Dis Child       Date:  1987-01       Impact factor: 3.791

7.  Transient neonatal diabetes mellitus: a relapse after 10 years of complete remission.

Authors:  M Vanelli; A De Fanti; S Cantoni; G Chiari
Journal:  Acta Diabetol       Date:  1994-06       Impact factor: 4.280

8.  Does glycemic control affect growth velocity in children with insulin-dependent diabetes mellitus.

Authors:  P Pitukcheewanont; R Alemzadeh; W R Jacobs; B H Jones; A J Eberle
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

9.  Insulin and growth in chronic renal failure.

Authors:  R H Mak; G B Haycock; C Chantler
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

10.  Development of height and weight in children with diabetes mellitus: report on two prospective multicentre studies, one cross-sectional, one longitudinal.

Authors:  A Thon; E Heinze; K D Feilen; R W Holl; H Schmidt; S Koletzko; U Wendel; J Nothjunge
Journal:  Eur J Pediatr       Date:  1992-04       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.